Soligenix (SNGX) Proxy filing summary

Executive summary

• Focus remains on maintaining Nasdaq listing to enhance liquidity, access to capital, and strategic flexibility, with a reverse stock split and increase in authorized shares proposed to support compliance and future growth.

• Pipeline includes diversified assets: HyBryte (discontinued Phase 3), SGX945 (promising Phase 2 for Behçet's disease), and ThermoVax® vaccine platform, with ongoing government-supported development.

• Strategic alternatives such as partnerships, licensing, mergers, acquisitions, and financing are being actively explored, though no definitive agreements have been reached.

• Forward-looking statements highlight risks and uncertainties, with ongoing evaluation of market valuation and stockholder value creation.

Voting matters and shareholder proposals

• Proposals include election of five directors, reverse stock split (1-for-2 to 1-for-20), increase in authorized shares (75M to 125M), advisory votes on executive compensation and its frequency, ratification of Cherry Bekaert LLP as auditor, and adjournment authority.

• Board recommends voting FOR all proposals and for annual advisory votes on executive compensation.

• Reverse stock split and authorized shares increase are aimed at maintaining Nasdaq compliance and supporting strategic transactions.

Board of directors and corporate governance

• Board consists of five experienced members with diverse backgrounds in pharma, biotech, and academia; average tenure is 14.2 years and average age is 70.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.

• Board leadership combines CEO and Chairman roles for decisive leadership, with independent directors providing oversight.

• Code of ethics and insider trading policy in place; incentive compensation recoupment policy adopted in 2023.